Chemoprevention for prostatic carcinoma

The role of flutamide in patients with prostatic intraepithelial neoplasia

Steven Robert Alberts, Michael L. Blute

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

High-grade prostatic intraepithelial neoplasia (HGPIN) is believed to be a precursor for prostatic adenocarcinoma. The prevalence of prostatic intraepithelial neoplasia (PIN) increases with advancing age. Autopsy studies suggest that PIN may precede the development of prostatic adenocarcinoma by up to 10 years. As such, HGPIN is believed to be a marker of increased risk. This provides a potential opportunity for chemoprevention. Flutamide is 1 agent with potential activity and limited side effects that may act to prevent or delay the onset of prostatic adenocarcinoma in men with HGPIN. A clinical trial is currently underway to assess the efficacy of flutamide.

Original languageEnglish (US)
Pages (from-to)188-190
Number of pages3
JournalUrology
Volume57
Issue number4 SUPPL. 1
StatePublished - 2001

Fingerprint

Prostatic Intraepithelial Neoplasia
Flutamide
Chemoprevention
Carcinoma
Adenocarcinoma
Autopsy
Clinical Trials

ASJC Scopus subject areas

  • Urology

Cite this

Chemoprevention for prostatic carcinoma : The role of flutamide in patients with prostatic intraepithelial neoplasia. / Alberts, Steven Robert; Blute, Michael L.

In: Urology, Vol. 57, No. 4 SUPPL. 1, 2001, p. 188-190.

Research output: Contribution to journalArticle

@article{250d64d941d44248ae364677b7449ed3,
title = "Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia",
abstract = "High-grade prostatic intraepithelial neoplasia (HGPIN) is believed to be a precursor for prostatic adenocarcinoma. The prevalence of prostatic intraepithelial neoplasia (PIN) increases with advancing age. Autopsy studies suggest that PIN may precede the development of prostatic adenocarcinoma by up to 10 years. As such, HGPIN is believed to be a marker of increased risk. This provides a potential opportunity for chemoprevention. Flutamide is 1 agent with potential activity and limited side effects that may act to prevent or delay the onset of prostatic adenocarcinoma in men with HGPIN. A clinical trial is currently underway to assess the efficacy of flutamide.",
author = "Alberts, {Steven Robert} and Blute, {Michael L.}",
year = "2001",
language = "English (US)",
volume = "57",
pages = "188--190",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4 SUPPL. 1",

}

TY - JOUR

T1 - Chemoprevention for prostatic carcinoma

T2 - The role of flutamide in patients with prostatic intraepithelial neoplasia

AU - Alberts, Steven Robert

AU - Blute, Michael L.

PY - 2001

Y1 - 2001

N2 - High-grade prostatic intraepithelial neoplasia (HGPIN) is believed to be a precursor for prostatic adenocarcinoma. The prevalence of prostatic intraepithelial neoplasia (PIN) increases with advancing age. Autopsy studies suggest that PIN may precede the development of prostatic adenocarcinoma by up to 10 years. As such, HGPIN is believed to be a marker of increased risk. This provides a potential opportunity for chemoprevention. Flutamide is 1 agent with potential activity and limited side effects that may act to prevent or delay the onset of prostatic adenocarcinoma in men with HGPIN. A clinical trial is currently underway to assess the efficacy of flutamide.

AB - High-grade prostatic intraepithelial neoplasia (HGPIN) is believed to be a precursor for prostatic adenocarcinoma. The prevalence of prostatic intraepithelial neoplasia (PIN) increases with advancing age. Autopsy studies suggest that PIN may precede the development of prostatic adenocarcinoma by up to 10 years. As such, HGPIN is believed to be a marker of increased risk. This provides a potential opportunity for chemoprevention. Flutamide is 1 agent with potential activity and limited side effects that may act to prevent or delay the onset of prostatic adenocarcinoma in men with HGPIN. A clinical trial is currently underway to assess the efficacy of flutamide.

UR - http://www.scopus.com/inward/record.url?scp=0035318820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035318820&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 188

EP - 190

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4 SUPPL. 1

ER -